Management of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
|
|
- Gregory Curtis
- 5 years ago
- Views:
Transcription
1 Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
2 When to Modify Therapy! Studies to date show better responses with earlier switches, as well as viral evolution at low-level viremia
3 Resistance Evolves Even With Stable Low-Level HIV Viremia! 80% of patients with VL <10,000 developed new RT or PI mutations over 8 months 1» Most common NRTI mutations: K70R, D67N, V118I, L74V! 90% of patients with VL <1,000 developed resistance over 14 months 2» Resistance to all on-treatment ARV was associated with VL increases >1000 ( progressive failure ) 1 Kantor, 9th CROI; 2002; Seattle. Abstract Coakley 9th CROI; 2002; Seattle. Abstract 556.; 2002;
4 Evolution of NRTI Resistance with Ongoing Virologic Failure (CNA 3005: AZT + 3TC + ABC) Plasma HIV-1 1 RNA Log Wild-Type 5000 c/ml 400 c/ml 50 c/ml M184V Only 28 Weeks ABC=5.9 ZDV=4.1 fold Accumulation of TAMs D67N/D, K70R/K, M184V M184V, Y215T/Y L41L/M, M184V, Y215Y L41L, L41L, M184V, M184V, Y215Y Y215Y L41L, M184V, L210L/W, Y215Y ABC=6.2 ZDV=12.2 fold Study Week Melby T, et al. 8 th CROI. Chicago, Abstract 448.
5 When to Modify Therapy! Studies to date show better responses with earlier switches, as well as viral evolution at low-level viremia! The risk of emergence of new mutations is highest in patients with little resistance
6 When to Modify Therapy! Studies to date show better responses with earlier switches, as well as viral evolution at low-level viremia! The risk of emergence of new mutations is highest in patients with little resistance! Early modification is especially important with regimens that contain low genetic barrier drugs (e.g. NNRTIs, 3TC, FTC)
7 HIV Lifecycle and Drug Targeting NRTI Target NEJM 340 (21), p.1620
8 NRTI Sequencing Options After Failure of Specific NRTI Backbones Initial Regimen AZT/3TC d4t/3tc AZT/3TC/ABC TDF/3TC TDF/FTC Likely Resistance Pattern M184V +/- TAMs M184V +/- K65R Most Active NRTIs Depends on number of TAMs and TAM pattern TDF or ddi may be most active NRTIs AZT + TDF + either 3TC or FTC (Resistance may be less common with FTC) ABC/3TC M184V +/- either L74V or K65R AZT + TDF + either 3TC or FTC Choose the next NRTIs based on resistance testing.
9 HIV Lifecycle and Drug Targeting NNRTI Target NEJM 340 (21), p.1620
10 NNRTI Resistance! Resistance mutations common at virologic failure» May occur as 1 st mutation, preceding M184V! Limited prospects for sequential use of current NNRTIs:» Poor results from NVP failure with 181C EFV» G190A/S, P225H cause DLV hypersusceptibility, but no clinical sequencing data» 2 nd generation NNRTIs promising: TMC125, TMC278
11 TMC125-C223: Virologic Response to Etravirine in Pts With NNRTI and PI Resistance OBR Alone (n = 40) Etravirine 400 mg BID (n = 80) Etravirine 800 mg BID (n = 79) 0.4 Weeks Mean (± SE) Change in VL (log 10 c/ml) [ITT: NC=F] * -1.18* *P <.05 Grossman HA, et al. ICAAC Abstract H- 416c.
12 TMC125-C223: NNRTI Mutations and Response to Etravirine at Week 24 Mean change in viral load (log 10 c/ml) TMC mg bid Active control N=79 N= *All subjects had NNRTI mutations from prior genotyping Baseline NNRTI mutations in TMC mg bid 0* N=15 N=18 N=17 N= Vingerhoets J, et al. 13th CROI, Denver, CO, February 5-5 8, Abst Relevant NNRTI Mutations: K101P, V179E, V179F, Y181I, Y181V, G190S, M230L
13 HIV Lifecycle and Drug Targets PI Target NEJM 340 (21), p.1620
14 Resistance Patterns after PI Failure Unboosted PIs! NFV:» 30N: no cross-resistance» 90M: cross-resistance! SQV:» 48V: no cross-resistance» 90M: cross resistance! ATV:» 50L: no cross-resistance! IDV:» Various mutations causing cross-resistance! FPV» I54L/M, V32I + I47V: Variable cross-resistance RTV-Boosted PIs! No PI resistance after failure of:» LPV/r» FPV/r» SQV/r» ATV/r Choose the next PI based on resistance testing.
15 Resistance at Time of First Virologic Failure TC 3TC 3TC 3TC Patients (%) TAMs NFV 3TC 20 TAMs IDV APV 0 ZDV 1 3TC ABC (n=39) ZDV 2 3TC IDV (n=17) ZDV 3 3TC APV (n=16) d4t 4 3TC NFV (n=96) d4t 4 3TC LPV/r (n=51) 1 Melby T. 8 th CROI, Abstract 448; 2 Havlir D, et al. JAMA. 2000;283: ; 3 Rusconi S, et al. Antiviral Ther ;3: Kempf D. 10 th CROI. Boston, Abstract 600
16 RESIST-1: Superior Virologic Responses With Tipranavir/Ritonavir Responders, % Patients with 1 log 10 VL reduction (ITT, NC=F) TPV/r (n = 311) CPI/r (n = 309) Wks 41.5% 22.3% P <.0001 Hicks C, et al. ICAAC Abstract 1137a.
17 Relationship of TPV Score to TPV Phenotype Results and Response TPV Score Median Change in VL at Wk 24 (log 10 copies/ml) (n = 144) (n = 242) (n = 260) (n = 68) (n = 4) TPV Score Mutations 10V, 13V, 20M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, 83D, 84V *24-week data from patients in RESIST-1 and -2 given TPV/r. Valdez H, et al. Resistance Workshop Abstract 27.
18 POWER: Subgroup Analyses of Response to Darunavir/r 600/100 BID Overall ENF Used (Naive) ENF Not Used 3 Primary PI Mut No Sensitive ARVs in OBR Darunavir/r 600/100 BID POWER-1 Cohort [1] 53% (n = 60) 18% (n = 60) 63% (n = 19) 22% (n = 18) 56% (n = 34) 19% (n = 36) 59% (n = 29) 9% (n = 35) 17% (n = 12) 0% (n = 9) Control POWER-2 Cohort [2] 7% (n = 53) 7% (n = 14) 30% (n = 20) 4% (n = 24) 7% (n = 28) 0% (n = 7) 18% (n = 11) 39% (n = 57) 35% (n = 23) 64% (n = 14) Patients with VL < 50 c/ml at Week 24 (%) (ITT NC=F) Patients With VL < 50 c/ml at Week 24 (%) Katlama C, et al. IAS Abstract WeOaLB Wilkin T, et al. ICAAC Abstract H-413.
19 Effect of Baseline Resistance on Response to Darunavir % With VL < 50 c/ml CPI Darunavir Overall Number of BL PI resistance-associated mutations (IAS-USA)! BL mutations associated with diminished response (< 33% with VL < 50 c/ml)» V11I, V32I, L33F, I47V, I50V, I54L, I54M, G73S, L76V, I84V and L89V (highlighted mutations emerged on therapy)» Presence associated with a higher number of PI mutations» Darunavir response remained higher than that of CPI DeMeyer S, et al. CROI Abstract 157.
20 HIV Lifecycle and Drug Targeting Entry Inhibitor target NEJM 340 (21), p.1620
21 gp 41 env Mutations Associated With Enfuvirtide Resistance: IAS-USA 2005 Enfuvirtide G 36 I 37 V 38 Q 39 Q 40 N 42 N 43 First heptad repeat (HR1 Region) D S V A M E R H T D
22 Maraviroc: Change in HIV RNA 0.5 Last day of dosing Change from baseline (log 10 HIV-1 copies/ml) Baseline Study A / UK-427,857 dose Placebo 015 Placebo mg QD 50 mg BID 100 mg QD 100 mg BID 150 mg BID Fast 150 mg BID Fed 300 mg QD 300 mg BID Time (day) n Fätkenheuer G et al.15 th IAC Abstract TuPeB4489
23 Update on CCR5 inhibitors Aplaviroc (GSK)! Phase IIb/III trials recently stopped due to hepatotoxicity! 4 (1%) treatment-emergent grade 3/4 ALT and total bilirubin >1.5x ULN Vicriviroc (Schering-Plough)! Study in ART-naïve stopped because of high rate of failure vs. EFV! May have been due to study design! Studies in experienced patients ongoing Maraviroc (Pfizer)! Studies ongoing in naive and experienced patients! 1 case with increased LFTs under review
24 TNX-355: Novel Entry Inhibitor! Anti-CD4 monoclonal antibody blocks gp120 attachment to CD4 receptor» Delivered by IV infusion! Phase II randomized trial in 82 3-class experienced patients [1]» TNX OBR or OBR alone» TNX-355 doses: 15 mg/kg IV every 2 wks 10 mg/kg IV every wk x 8 wks, then 10 mg/kg every 2 wks Mean Change in VL at Week 24 (log 10 c/ml) OBR alone TNX OBR 15 mg/kg (P =.003) 10 mg/kg (P <.001) Norris D, et al. ICAAC Abstract LB2-26..
25 HIV Lifecycle and Drug Targets Integrase Inhibitors NEJM 340 (21), p.1620
26 Integrase Inhibitor: MK-0518 Triple-class resistant by genotype/phenotype CD4 > 300 cells/mm³ VL > 5000 c/ml Placebo (n = 43) MK BID (n = 40) MK BID (n = 42) MK BID (n = 42) All combined with OBR No Active PIs, % Weeks! Multicenter, double-blind randomized study! Preliminary data reported! Endpoints» HIV-1 RNA, CD4 counts at 16 weeks» Safety! No boosting effect of ritonavir with this compound 16 Grinsztejn B, et al. CROI Abstract 159LB.
27 MK-0518: Viral Suppression < 400 c/ml Through Week Observed data Patients With VL < 400 c/ml (%) MK mg MK mg MK mg OBT alone Week Grinsztejn B, et al. CROI Abstract 159LB.
28 MK-0518: Viral Suppression < 50 c/ml Through Week Observed Data Patients With VL < 50 c/ml (%) MK mg MK mg MK mg OBT alone Week ! Adverse events similar to placebo Grinsztejn B, et al. CROI Abstract 159LB
29 HIV Lifecycle and Drug Targets Maturation Inhibitors NEJM 340 (21), p.1620
30 Maturation Inhibitors (PA-457): Blocks cleavage of capsid precursor to mature p24 Viral Budding and Maturation
31 PA-457: Virologic Response to Novel Maturation Inhibitor Monotherapy! Randomized, phase IIa study of 10-day monotherapy in 32 HIV-infected pts PL (n = 8) PA-457 Dose (mg/d) 25 (n = 6) 50 (n = 6) 100 (n = 6) 200 (n = 6)» Med. 1 log 10 VL reduction with PA mg/d! Generally well tolerated Median Change in VL at Day 10 (log 10 c/ml) (P =.02) (P =.004) (P <.0001) Beatty G, et al. ICAAC Abstract H- 416d.
32 Goals of Therapy With Multi-Drug Resistant HIV! Access to 2 active agents:» Completely suppress viral load» Now applies to an increasing number of salvage patients! Access to < 2 active agents:» Reduce viral load by >1 log 10» Stabilize CD4 count» Minimize drug toxicity» Prevent clinical progression and death» Avoid new resistance mutations that could eliminate future options» Avoid monotherapy with new drugs
33 Considerations for Salvage Therapy! In combination therapy, only the active drugs count
34 In Combination Therapy, Only the Active Drugs Count Patients with HIV RNA < 400 c/ml at Week 48 (%) 100 ENF + OB OB * * P <.05 0 * 30 8 DC + VF = Failure * * ENF: OB: Baseline GSS * 25 Miralles D, et al. ICDT- HIV 2004.
35 Considerations for Salvage Therapy! In combination therapy, only the active drugs count! A new drug may not be an active drug
36 Considerations for Salvage Therapy! In combination therapy, only the active drugs count! A new drug may not be an active drug! When to use a new drug, and when to wait
37 When to Use a New Drug, and When to Wait! What is prognosis with continued nonsuppressive therapy?! What are the resistance consequences of continued non-suppressive therapy?! How can I maintain the right mutations without allowing the wrong ones to emerge?! When will new drugs be available, and will they be active against the patients virus?
38 CD4-VL Disconnect: Can Impaired Fitness Be Used Strategically? CD Transient Complete Weeks Log HIV RNA Deeks. J Infect Dis 2000;181:946.
39 Continued Therapy in Patients With Virologic Failure: A Delicate Balance Maintain mutations Decrease fitness Delay progression Accumulate new mutations Develop resistance to drugs in development
40 Considerations for Salvage Therapy! In combination therapy, only the active drugs count! A new drug may not be an active drug! When to use a new drug, and when to wait! Waiting: Choosing a holding regimen
41 The Cost of Treatment Interruption in Treatment-Experienced Patients VL* Median Change in (log 10 c/ml) Median Change in CD4 Count (cells/mm 3 ) n = n = Weeks Before and After WT Switch *3 subjects excluded because baseline VL near upper LOQ Deeks SG, et al. N Engl J Med. 2001;344:
42 Partial Treatment Interruption Discontinue PIs, continue NRTIs (n = 15) Discontinue NRTIs, continue PIs (n = 5) Change in HIV-1 RNA (log 10 copies/ml) l Change in CD4+ Cel Count (cells/mm 3 ) Wk 8 Wk 12 Wk Wk 8 Wk 12 Wk Deeks SG, et al. J Infect Dis. 2005;192:
43 Guidelines for Choosing a Non- Suppressive Holding Regimen! Never use an NNRTI» NNRTI mutations have no beneficial impact on fitness» Accumulation of additional mutations may result in crossresistance to 2 nd generation NNRTIs! Always use 3TC or FTC» Simple and well tolerated drugs» M184V decreases fitness» Increased activity of AZT, d4t, TDF! Choose PIs and/or NNRTIs based on resistance and tolerability/toxicity considerations
44 Timeline for New Antiretrovirals Entry inhibitors (anti-gp120, CCR5) Maturation inhibitors Integrase inhibitors CXCR4 inhibitors Integrase inhibitors CCR5 inhibitors PA Darunavir Etravirine TMC278 Dexelvucitabine Brecanavir PIs NNRTI NRTI
45 Using of New Agents: Too Soon, Too Late, or Just Right?! Too soon:» New drug used in combination with inactive or partially active drugs despite relatively preserved CD4 count! Too late:» New drug deferred until the patient s virus is resistant to all other available drugs! Just right:» New drug combined with other active new agents, or use deferred until other new agents available
46
2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationThe New Agents: Management of Experienced Patients and Resistance. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
The New Agents: Management of Experienced Patients and Resistance Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine T.D. 45 year old man with HIV infection diagnosed in 2000 On multiple
More informationNew Hope for Treatment Experienced HIV (+) Patients. Treatment Experienced. Drug Resistance: Estimated Prevalence. Patients in the US- Estimate
New Hope for Treatment Experienced HIV (+) Patients Nelson Vergel www.salvagetherapies.org HIV/AIDS Pandemic 23: Adults and Children Living With HIV/AIDS 47% of Cases are Women 15.6% Eastern Europe Western
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationJosep Mallolas Hospital Clínic Barcelona
Nuevos paradigmas en la infección VIH Josep Mallolas Hospital Clínic Barcelona 1. Do you believe, I have to start ARV therapy? Incidence and Mortality of AIDS in Spain HIV and NON-AIDS complications HIV
More informationNew Antiretroviral Therapies and Classes. Douglas G. Fish, MD Albany Medical College Albany, NY Cali,, Colombia March 29, 2007
New Antiretroviral Therapies and Classes Douglas G. Fish, MD Albany Medical College Albany, NY Cali,, Colombia March 29, 27 Overview New therapies existing classes Investigational antiretrovirals Monoclonal
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationKiat Ruxrungtham. Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre
Kiat Ruxrungtham Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre www.iasusa.org; www.aidsinfo.nih.gov; www.clinicaloptions.com; www.clinicaloptions.com/hiv
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationHistory (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11
(August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More information12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter
EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationBHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh
BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 ANTIRETROVIRAL TREATMENT STRATEGIES AND NEW DRUGS A5202:
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationPharmacology Update Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005
Pharmacology Update 2005 Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005 I m having a Maalox moment!!! Gastric Hypoacidity in HIV 20% incidence in HIV (unrelated to CD 4 ) Antacids, ddi tablets, H2-blockers
More informationHIV Virology & Resistance
Themes Viral load Tropism Drug resistance HIV Virology & Resistance Anna Maria Geretti Institute of Infection & Global Health The HIV Virology Timeline HIV-1 isolated HIV replicates at high levels throughout
More information13 th Conference on Retroviruses and Opportunistic Infections (CROI)
REPORT FROM 13 th Conference on Retroviruses and Opportunistic Infections (CROI) February 5 8, 5 2006 Denver, CO 1 Tipranavir Significantly Reduces Concentrations of Other ARVs -10 % change PK -30-50 -70-68
More informationHIV infection and Primary Care. HIV Care in /30/2013. It s not the AIDS of 85. Stephen Raffanti MD MPH Vanderbilt University School of Medicine
HIV infection and Primary Care Stephen Raffanti MD MPH Vanderbilt University School of Medicine HIV Care in 2013 Chronic lifelong treatment with all the associated issues: medication tolerability medication
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question 12/6/2017
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationART Treatment. ART Treatment
Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationFirst-Line Antiretroviral Therapy for Treatment and Prevention:
First-Line Antiretroviral Therapy for Treatment and Prevention: The Past, Present and Future Best Options Joel Gallant, MD, MPH Johns Hopkins University School of Medicine IAS-USA Guidelines 7/2008: When
More informationFriday afternoon Programme
Friday afternoon Programme Pharmacology and TDM Dr Marta Boffito Consultant Physician, C&W Resistance to new anti-retrovirals Dr Steve Taylor Consultant Physician, Birmingham HIVPA Annual Conference 2008
More informationHIV replication and selection of resistance: basic principles
HIV replication and selection of resistance: basic principles 26th International HIV Drug Resistance and Treatment Strategies Workshop Douglas Richman 6 November 2017 CLINICAL DATA DURING SIXTEEN WEEKS
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationProfessor Jeffery Lennox
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Professor Jeffery Lennox Emory University School of Medicine Atlanta, Georgia, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationPerspectivesconcernantles InhibiteursNon Nucléosidiquesde la Transcriptase Inverse (INNTI)
Perspectivesconcernantles InhibiteursNon Nucléosidiquesde la Transcriptase Inverse (INNTI) Gianni Di Perri Dept. de Maladies Infectieuses Universitè de Turin Ospedale Amedeo di Savoia Fusion inhibitors
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationThe Eras of the HIV Epidemic
The Eras of the HIV Epidemic 1930-1980 1981-1986 1987-1995 1996-2005 2nd Gen. HAART 2006-2011 2006: Disproportionate distribution of HIV 2006: Gates and Clinton at International AIDS conference announce
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationUpdate on HIV-1 Drug Resistance and Tropism Testing
Update on HIV-1 Drug Resistance and Tropism Testing Daniel R. Kuritzkes, MD Section of Retroviral Therapeutics Brigham and Women s Hospital Harvard Medical School ACTHIV 2011: A State-of-the-Science Conference
More informationAdvances in HIV Treatment: When to Start Treatment Which Antivirals to Use
Advances in HIV Treatment: When to Start Treatment Which Antivirals to Use Calvin Cohen MD Harvard Vanguard Medical Associates CRI New England Vice Chair, Science Steering Cmte, INSIGHT Boston MA Learning
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationThe advent of protease inhibitors (PIs) as PROCEEDINGS CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD
CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD ABSTRACT Tremendous strides were made in reducing the morbidity and mortality associated with HIV infection with
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationEuropean Guidelines. for the Clinical Management and Treatment of HIV Infected Adults
European Guidelines for the Clinical Management and Treatment of HIV Infected Adults 2005 These Euroguidelines result from the comparison of guidelines from several European countries and from a discussion
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationImproving PI drug resistance scores. Jens Verheyen, MD Institute of Virology University Duisburg-Essen
Improving PI drug resistance scores Jens Verheyen, MD Institute of Virology University Duisburg-Essen Overview Why can all PI drug resistance scores be improved? Do we still need to improve PI drug resistance
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationAdvanced Resistance Issues for the Clinician
Advanced Resistance Issues for the Clinician Stephen Raffanti MD MPH CMO, Comprehensive Care Center Associate Director HIV Clinical Services Vanderbilt University School of Medicine Goals of this talk
More informationADVANCES IN ANTI RETROVIRAL THERAPY. E. Omonge UON
ADVANCES IN ANTI RETROVIRAL THERAPY E. Omonge UON KAP September 2008 Current Antiretroviral Medications PI NRTI Amprenavir APV Abacavir ABC Atazanavir ATV Didanosine DDI Darunavir DRV Emtricitabine FTC
More informationCROI 2013: New Drugs for Treatment and PrEP
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2013: New Drugs for Treatment and PrEP Brian R. Wood, MD Medical Director, NW AETC Project ECHO Assistant Professor of Medicine, University of Washington
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationThe Use of Resistance Testing in HIV
The Use of Resistance Testing in HIV Dushyantha Jayaweera, M.D., M.R.C.O.G., F.A.C.P. Professor in Clinical Medicine Division of Infectious Diseases University of Miami Miller School of Medicine Viral
More informationART for HIV Prevention:
ART for HIV Prevention: KENNETH H. MAYER, M.D. Brown University/The Fenway Institute August 22, 2009 APPROACHES TO PREVENT HIV TRANSMISSION DECREASE SOURCE OF INFECTION Barrier Protection Treat STI Antiretroviral
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationANTIRETROVIRAL TOXICITY Strategies for prevention and treatment
ANTIRETROVIRAL TOXICITY Strategies for prevention and treatment Francisco Antunes Professor da Faculdade de Medicina da Universidade de Lisboa e Director do Serviço de Doenças Infecciosas do Hospital de
More informationHIV Drug Resistance and How to Manage HAART failure
HIV Drug Resistance and How to Manage HAART failure Kiat Ruxrungtham Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre Targets of Antiretroviral Agents RT
More informationReduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationCases from the Clinic(ians): Case-Based Panel Discussion
Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: 03-12-14 Learning Objectives After attending this presentation,
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationEfficacy and Safety of Doravirine 100mg QD vs Efavirenz 600mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results
Efficacy and Safety of Doravirine 1mg QD vs Efavirenz 6mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results Jose M. Gatell, Francois Raffi, Andreas Plettenberg, Don Smith, Joaquin Portilla,
More informationVirological failure in children. Dr Lee Fairlie
Virological failure in children Dr Lee Fairlie Case 1 Thembi is a 34 year old female. She is HIV infected She lives in JHB and her 2 children, Lerato and Sipho live in Mpumalanga with Gogo They are both
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationHIV Drug Resistance Update 2007
HIV Drug Resistance Update 27 Harry Lampiris, MD Associate Professor of Clinical Medicine, UCSF Infectious Disease Section Department of Medicine San Francisco VA Medical Center Outline Indications for
More informationAntiretroviral Therapy
Antiretroviral Therapy Scott M. Hammer, M.D. 1986 1990 ZDV monorx 1990 1995 Alternative NRTI monorx Combination NRTI Rx Introduction of NNRTI s Antiretroviral resistance Pathogenetic concepts Evolution
More informationProfessor José Arribas
19 th Annual Conference of the British HIV Association (BHIVA) Professor José Arribas Hospital La Paz, Madrid, Spain 16-19 April 2013, Manchester Central Convention Complex Can we live without nucleosides?
More informationSwitching strategies and ARV treatment costs
February 2014 Switching strategies and ARV treatment costs Josep M Llibre/Bonaventura Clotet Fundació Lluita contra la SIDA Hosp Univ Germans Trias i Pujol Badalona Rationale. Spain is under a huge economic
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationART: The New, The Old and The Ugly
ART: The New, The Old and The Ugly Our Current ARVS The Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs/ NtRTIs) Abacavir Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine The Non-Nucleoside
More informationWhole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy
Whole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy K El Bouzidi 1,, RP Datir 1, V Kwaghe 3, S Roy 1, D Frampton
More informationIntegrase Inhibitors in the Treatment HIV-Infection. Andrew Zolopa, MD Stanford University
Integrase Inhibitors in the Treatment HIV-Infection Andrew Zolopa, MD Stanford University 1 IAS-USA 212 Guidelines Updated Recommendations When to start ART is now recommended for all patients, regardless
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationWhen to Start HIV Treatment? Which Treatments to Start?
When to Start HIV Treatment? Which Treatments to Start? Calvin Cohen MD Harvard Medical School Harvard Vanguard Medical Associates CRI New England Vice Chair, Science Steering Cmte, INSIGHT Boston USA
More informationSELECTING THE BEST ART FOR EACH PATIENT
SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May
More informationTreating HIV: When the Guidelines Don t Fit. Joel Gallant, MD, MPH. Southwest CARE Center Santa Fe, New Mexico
Treating HIV: When the Guidelines Don t Fit Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, New Mexico Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures
More information